The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
Abstract
BACKGROUND: Biologic agents offer a range of new therapeutic options for patients with psoriasis; however, the relative benefit-risk profiles of such therapies are not well known. We compared two biologic agents, ustekinumab (an interleukin-12 and interleukin-23 blocker) and etanercept (an inhibitor of tumor necrosis factor alpha), for the treatment of psoriasis. METHODS: We randomly assigned 903 patients with moderate-to-severe psoriasis to receive subcutaneous injections of either 45 or 90 mg of ustekinumab (at weeks 0 and 4) or high-dose etanercept (50 mg twice weekly for 12 weeks). The primary end point was the proportion of patients with at least 75% improvement in the psoriasis area-and-severity index (PASI) at week 12; a secondary end point was the proportion with cleared or minimal disease on the basis of the physician's global assessment. Assessors were unaware of the treatment assignments. The efficacy and safety of a crossover from etanercept to ustekinumab were evaluated after week 12. RESULTS: There was at least 75% improvement in the PASI at week 12 in 67.5% of patients who received 45 mg of ustekinumab and 73.8% of patients who received 90 mg, as compared with 56.8% of those who received etanercept (P=0.01 and P<0.001, respectively). Similarly, 65.1% of patients who received 45 mg of ustekinumab and 70.6% of patients who received 90 mg of ustekinumab had cleared or minimal disease according to the physician's global assessment, as compared with 49.0% of those who received etanercept (P<0.001 for both comparisons). Among patients who did not have a response to etanercept, 48.9% had at least 75% improvement in the PASI within 12 weeks after crossover to ustekinumab. One or more adverse events occurred through week 12 in 66.0% of patients who received 45 mg of ustekinumab and 69.2% of patients who received 90 mg of ustekinumab and in 70.0% who received etanercept; 1.9%, 1.2%, and 1.2%, respectively, had serious adverse events. Safety patterns were similar before and after crossover from etanercept to ustekinumab. CONCLUSIONS: The efficacy of ustekinumab at a dose of 45 or 90 mg was superior to that of high-dose etanercept over a 12-week period in patients with psoriasis. (ClinicalTrials.gov number, NCT00454584.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Severe Psoriasis – Oral Therapy with a New Retinoid
Fredriksson, T., & Pettersson, U. (2009) · Dermatologica · doi:10.1159/000250839 · Cited by 2,718
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Pathogenesis and clinical features of psoriasis
Griffiths, C. E., & Barker, J. N. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61128-3 · Cited by 2,158
Self-citationLeonardi, C. L., Kimball, A. B., Papp, K. A., Yeilding, N., Guzzo, C., Wang, Y., Li, S., Dooley, L. T., & Gordon, K. B. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60725-4 · Cited by 1,874
Self-citationAcosta-Rodriguez, E. V., Napolitani, G., Lanzavecchia, A., & Sallusto, F. (2007) · Nature Immunology · doi:10.1038/ni1496 · Cited by 1,857
The Biological Functions of T Helper 17 Cell Effector Cytokines in Inflammation
Ouyang, W., Kolls, J. K., & Zheng, Y. (2008) · Immunity · doi:10.1016/j.immuni.2008.03.004 · Cited by 1,700
Papp, K. A., Langley, R. G., Lebwohl, M., Krueger, G. G., Szapary, P., Yeilding, N., Guzzo, C., Hsu, M.-C., Wang, Y., Li, S., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60726-6 · Cited by 1,361
Self-citationEtanercept as Monotherapy in Patients with Psoriasis
Leonardi, C. L., Powers, J. L., Matheson, R. T., Goffe, B. S., Zitnik, R., Wang, A., & Gottlieb, A. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030409 · Cited by 1,175
Hehlgans, T., & Pfeffer, K. (2005) · Immunology · doi:10.1111/j.1365-2567.2005.02143.x · Cited by 1,048
Reich, K., Nestle, F. O., Papp, K., Ortonne, J.-P., Evans, R., Guzzo, C., Li, S., Dooley, L. T., & Griffiths, C. E. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67566-6 · Cited by 1,045
Self-citation
Cited by
Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review
Armstrong, A. W., & Read, C. (2020) · JAMA · doi:10.1001/jama.2020.4006 · Cited by 2,335
Secukinumab in plaque psoriasis—results of two phase 3 trials
Langley, R. G., Elewski, B. E., Lebwohl, M., Reich, K., Griffiths, C. E. M., Papp, K., Puig, L., Nakagawa, H., Spelman, L., Sigurgeirsson, B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314258 · Cited by 1,997
Innate IL-17-producing cells: the sentinels of the immune system
Cua, D. J., & Tato, C. M. (2010) · Nature Reviews Immunology · doi:10.1038/nri2800 · Cited by 1,578
Functional Specialization of Interleukin-17 Family Members
Iwakura, Y., Ishigame, H., Saijo, S., & Nakae, S. (2011) · Immunity · doi:10.1016/j.immuni.2011.02.012 · Cited by 1,289
European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa
Zouboulis, C. C., Desai, N., Emtestam, L., Hunger, R. E., Ioannides, D., Juhász, I., Lapins, J., Matusiak, L., Prens, E. P., Revuz, J., et al. (2015) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.12966 · Cited by 1,093
Pivotal Role of Dermal IL-17-Producing γδ T Cells in Skin Inflammation
Cai, Y., Shen, X., Ding, C., Qi, C., Li, K., Li, X., Jala, V. R., Zhang, H.-G., Wang, T., Zheng, J., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.08.001 · Cited by 1,026
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
Menter, A., Strober, B. E., Kaplan, D. H., Kivelevitch, D., Prater, E. F., Stoff, B., Armstrong, A. W., Connor, C., Cordoro, K. M., Davis, D. M. R., et al. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.11.057 · Cited by 969
Self-citationInflammatory bone loss: pathogenesis and therapeutic intervention
Redlich, K., & Smolen, J. S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3669 · Cited by 830
Adverse effects of biologics: a network meta-analysis and Cochrane overview
Singh, J. A., Wells, G. A., Christensen, R., Tanjong Ghogomu, E., Maxwell, L. J., MacDonald, J. K., Filippini, G., Skoetz, N., Francis, D. K., Lopes, L. C., et al. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008794.pub2 · Cited by 823
McInnes, I. B., Kavanaugh, A., Gottlieb, A. B., Puig, L., Rahman, P., Ritchlin, C., Brodmerkel, C., Li, S., Wang, Y., Mendelsohn, A. M., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60594-2 · Cited by 807
Self-citationAlinaghi, F., Calov, M., Kristensen, L. E., Gladman, D. D., Coates, L. C., Jullien, D., Gottlieb, A. B., Gisondi, P., Wu, J. J., Thyssen, J. P., et al. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.06.027 · Cited by 673
Ritchlin, C., Rahman, P., Kavanaugh, A., McInnes, I. B., Puig, L., Li, S., Wang, Y., Shen, Y.-K., Doyle, M. K., Mendelsohn, A. M., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204655 · Cited by 662
Self-citationType I/II cytokines, JAKs, and new strategies for treating autoimmune diseases
Schwartz, D. M., Bonelli, M., Gadina, M., & O'Shea, J. J. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.167 · Cited by 648
New IBD genetics: common pathways with other diseases
Lees, C. W., Barrett, J. C., Parkes, M., & Satsangi, J. (2011) · Gut · doi:10.1136/gut.2009.199679 · Cited by 635
Pathophysiology of atopic dermatitis: Clinical implications
Kim, J., Kim, B. E., & Leung, D. Y. M. (2019) · Allergy and Asthma Proceedings · doi:10.2500/aap.2019.40.4202 · Cited by 635
Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis
Hawkes, J. E., Yan, B. Y., Chan, T. C., & Krueger, J. G. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800013 · Cited by 593
Thaçi, D., Blauvelt, A., Reich, K., Tsai, T.-F., Vanaclocha, F., Kingo, K., Ziv, M., Pinter, A., Hugot, S., You, R., et al. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.05.013 · Cited by 551
Kaymaz, K., & Beikler, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20143394 · Cited by 534
Rorγt+ innate lymphocytes and γδ T cells initiate psoriasiform plaque formation in mice
Pantelyushin, S., Haak, S., Ingold, B., Kulig, P., Heppner, F. L., Navarini, A. A., & Becher, B. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61862 · Cited by 512
Singh, J. A., Guyatt, G., Ogdie, A., Gladman, D. D., Deal, C., Deodhar, A., Dubreuil, M., Dunham, J., Husni, M. E., Kenny, S., et al. (2019) · Arthritis & Rheumatology · doi:10.1002/art.40726 · Cited by 493
Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges
Smolen, J. S., & Aletaha, D. (2015) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.8 · Cited by 474
Singh, J. A., Guyatt, G., Ogdie, A., Gladman, D. D., Deal, C., Deodhar, A., Dubreuil, M., Dunham, J., Husni, M. E., Kenny, S., et al. (2019) · Arthritis Care & Research · doi:10.1002/acr.23789 · Cited by 466
British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009
Smith, C. H., Anstey, A. V., Barker, J. N. W. N., Burden, A. D., Chalmers, R. J. G., Chandler, D. A., Finlay, A. Y., Griffiths, C. E. M., Jackson, K., McHugh, N. J., et al. (2009) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2009.09505.x · Cited by 464
Self-citationThe Th17 pathway and inflammatory diseases of the intestines, lungs, and skin
Weaver, C. T., Elson, C. O., Fouser, L. A., & Kolls, J. K. (2013) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130318 · Cited by 462
Guidelines of care for the management of psoriasis and psoriatic arthritis
Menter, A., Korman, N. J., Elmets, C. A., Feldman, S. R., Gelfand, J. M., Gordon, K. B., Gottlieb, A., Koo, J. Y. M., Lebwohl, M., Leonardi, C. L., et al. (2011) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2010.11.055 · Cited by 460
Self-citationGossec, L., Smolen, J. S., Gaujoux-Viala, C., Ash, Z., Marzo-Ortega, H., van der Heijde, D., FitzGerald, O., Aletaha, D., Balint, P., Boumpas, D., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-200350 · Cited by 446
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Sbidian, E., Chaimani, A., Garcia-Doval, I., Do, G., Hua, C., Mazaud, C., Droitcourt, C., Hughes, C., Ingram, J. R., Naldi, L., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011535.pub2 · Cited by 433
Signaling pathways and targeted therapies for psoriasis
Guo, J., Zhang, H., Lin, W., Lu, L., Su, J., & Chen, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01655-6 · Cited by 427
Papp, K. A., Griffiths, C. E. M., Gordon, K., Lebwohl, M., Szapary, P. O., Wasfi, Y., Chan, D., Hsu, M.-C., Ho, V., Ghislain, P. D., et al. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12214 · Cited by 415
Self-citationJorn Bovenschen, H., van de Kerkhof, P. C., van Erp, P. E., Woestenenk, R., Joosten, I., & Koenen, H. J. P. M. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.139 · Cited by 415
Self-citationTopical delivery of siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation
Zheng, D., Giljohann, D. A., Chen, D. L., Massich, M. D., Wang, X.-Q., Iordanov, H., Mirkin, C. A., & Paller, A. S. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1118425109 · Cited by 409
Genome-wide association studies of cancer: current insights and future perspectives
Sud, A., Kinnersley, B., & Houlston, R. S. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.82 · Cited by 393
New insights of T cells in the pathogenesis of psoriasis
Cai, Y., Fleming, C., & Yan, J. (2012) · Cellular & Molecular Immunology · doi:10.1038/cmi.2012.15 · Cited by 389
Inflammation in atherosclerosis
Taleb, S. (2016) · Archives of Cardiovascular Diseases · doi:10.1016/j.acvd.2016.04.002 · Cited by 375
Genomics and the Multifactorial Nature of Human Autoimmune Disease
Cho, J. H., & Gregersen, P. K. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1100030 · Cited by 354
The Multitasking Organ: Recent Insights into Skin Immune Function
Di Meglio, P., Perera, G. K., & Nestle, F. O. (2011) · Immunity · doi:10.1016/j.immuni.2011.12.003 · Cited by 348
Benson, J. M., Peritt, D., Scallon, B. J., Heavner, G. A., Shealy, D. J., Giles-Komar, J. M., & Mascelli, M. A. (2011) · mAbs · doi:10.4161/mabs.3.6.17815 · Cited by 340
Interleukin‐23: as a drug target for autoimmune inflammatory diseases
Tang, C., Chen, S., Qian, H., & Huang, W. (2012) · Immunology · doi:10.1111/j.1365-2567.2011.03522.x · Cited by 337
Di Meglio, P., Villanova, F., & Nestle, F. O. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a015354 · Cited by 317
Cytokines as Therapeutic Targets in Rheumatoid Arthritis and Other Inflammatory Diseases
Siebert, S., Tsoukas, A., Robertson, J., & McInnes, I. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009639 · Cited by 307
A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis
Gordon, K. B., Duffin, K. C., Bissonnette, R., Prinz, J. C., Wasfi, Y., Li, S., Shen, Y.-K., Szapary, P., Randazzo, B., & Reich, K. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501646 · Cited by 306
Self-citationSuárez-Fariñas, M., Li, K., Fuentes-Duculan, J., Hayden, K., Brodmerkel, C., & Krueger, J. G. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.184 · Cited by 305
Tillack, C., Ehmann, L. M., Friedrich, M., Laubender, R. P., Papay, P., Vogelsang, H., Stallhofer, J., Beigel, F., Bedynek, A., Wetzke, M., et al. (2014) · Gut · doi:10.1136/gutjnl-2012-302853 · Cited by 302
Nash, P., Kerschbaumer, A., Dörner, T., Dougados, M., Fleischmann, R. M., Geissler, K., McInnes, I., Pope, J. E., van der Heijde, D., Stoffer-Marx, M., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-218398 · Cited by 299
Kavanaugh, A., Ritchlin, C., Rahman, P., Puig, L., Gottlieb, A. B., Li, S., Wang, Y., Noonan, L., Brodmerkel, C., Song, M., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204741 · Cited by 295
Self-citationComparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis
Armstrong, A. W., Puig, L., Joshi, A., Skup, M., Williams, D., Li, J., Betts, K. A., & Augustin, M. (2020) · JAMA Dermatology · doi:10.1001/jamadermatol.2019.4029 · Cited by 294
Ryan, C., Leonardi, C. L., Krueger, J. G., Kimball, A. B., Strober, B. E., Gordon, K. B., Langley, R. G., de Lemos, J. A., Daoud, Y., Blankenship, D., et al. (2011) · JAMA · doi:10.1001/jama.2011.1211 · Cited by 289
Self-citationInterleukin-23: A key cytokine in inflammatory diseases
Duvallet, E., Semerano, L., Assier, E., Falgarone, G., & Boissier, M.-C. (2011) · Annals of Medicine · doi:10.3109/07853890.2011.577093 · Cited by 282
Mease, P. J., & Armstrong, A. W. (2014) · Drugs · doi:10.1007/s40265-014-0191-y · Cited by 271
Langley, R. G. B., Feldman, S. R., Nyirady, J., van de Kerkhof, P., & Papavassilis, C. (2015) · Journal of Dermatological Treatment · doi:10.3109/09546634.2013.865009 · Cited by 264
Self-citationDi Meglio, P., Di Cesare, A., Laggner, U., Chu, C.-C., Napolitano, L., Villanova, F., Tosi, I., Capon, F., Trembath, R. C., Peris, K., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017160 · Cited by 262
Poddubnyy, D., Hermann, K.-G. A., Callhoff, J., Listing, J., & Sieper, J. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204248 · Cited by 260
IL-17 and Th17 Cells in Atherosclerosis: Subtle and Contextual Roles
Taleb, S., Tedgui, A., & Mallat, Z. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.114.303567 · Cited by 260
Cho, J. H., & Feldman, M. (2015) · Nature Medicine · doi:10.1038/nm.3897 · Cited by 260
Winthrop, K. L., Mariette, X., Silva, J. T., Benamu, E., Calabrese, L. H., Dumusc, A., Smolen, J. S., Aguado, J. M., & Fernández-Ruiz, M. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.02.002 · Cited by 259
McGinley, A. M., Sutton, C. E., Edwards, S. C., Leane, C. M., DeCourcey, J., Teijeiro, A., Hamilton, J. A., Boon, L., Djouder, N., & Mills, K. H. G. (2020) · Immunity · doi:10.1016/j.immuni.2020.01.002 · Cited by 248
What's fueling the biotech engine—2012 to 2013
(Rob) Aggarwal, S. (2014) · Nature Biotechnology · doi:10.1038/nbt.2794 · Cited by 254
McGonagle, D. G., McInnes, I. B., Kirkham, B. W., Sherlock, J., & Moots, R. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-215356 · Cited by 254
T cells and the skin: from protective immunity to inflammatory skin disorders
Ho, A. W., & Kupper, T. S. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0162-3 · Cited by 241
Biologics for targeting inflammatory cytokines, clinical uses, and limitations
Rider, P., Carmi, Y., & Cohen, I. (2016) · International Journal of Cell Biology · doi:10.1155/2016/9259646 · Cited by 226
IL-12-and IL-23 in health and disease
Croxford, A. L., Kulig, P., & Becher, B. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.07.017 · Cited by 160
Therapeutic potential of targeting IL‐17 and IL‐23 in sepsis
Bosmann, M., & Ward, P. A. (2012) · Clinical and Translational Medicine · doi:10.1186/2001-1326-1-4 · Cited by 42
Wan, J., Abuabara, K., Troxel, A. B., Shin, D. B., Van Voorhees, A. S., Bebo, B. F., Krueger, G. G., Callis Duffin, K., & Gelfand, J. M. (2012) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2011.03.012 · Cited by 41
Bai, J. P. F., Schmidt, B. J., Gadkar, K. G., Damian, V., Earp, J. C., Friedrich, C., van der Graaf, P. H., Madabushi, R., Musante, C. J., Naik, K., et al. (2021) · The AAPS Journal · doi:10.1208/s12248-021-00585-x · Cited by 38
Metadata
- Authors
- Griffiths, C. E. M., Strober, B. E., van de Kerkhof, P., Ho, V., Fidelus-Gort, R., Yeilding, N., Guzzo, C., Xia, Y., Zhou, B., Li, S., Dooley, L. T., Goldstein, N. H., & Menter, A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-01-14
- Volume
- 362
- Issue
- 2
- Pages
- 118-128
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2149566497
- Cited by
- 859
- References
- 29
- FWCI
- 32.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.